GCs exhibit therapeutic effects by interacting with glucocorticoid receptor (GR) and cellular transcription factors (e.g., NF-λB and AP-1) (Robertson et al., 2010) that decrease proinflammatory, antiapoptotic, and survival gene expression, and these effects ultimately lead to tumor cell death (Chen et al., 2010). Here, NR3C1 is linked to neoplasm.